MANGOCEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MANGOCEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $456.0K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $615.9K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $731.5K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $8.9K | Apr 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.4K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $380.0K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $431.5K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.9K | Apr 1, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.64M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($8.71M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($9.21M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($2.00M) | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.03M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($7.97M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($9.22M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.99M) | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.85M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($4.86M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($7.00M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.35M) | Apr 1, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $3.5K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $43.1K | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.09M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $15.37M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $1.05M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.00M | Apr 1, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $890.6K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $1.43M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $276.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $389.3K | Apr 1, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.20M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $13.95M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $774.8K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $614.0K | Apr 1, 2024 |
| FY2023 | Dec 31, 2021 | ($16.7K) | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.65M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($20.00M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($11.23M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($2.02M) | Apr 1, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $58.7K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $739.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $682.9K | Apr 1, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.89M | Apr 1, 2026 |
| FY2025 | Jun 2, 2025 | 93,731 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 3.25M | Apr 1, 2026 |
| FY2025 | Oct 16, 2024 | 2.13M | Apr 1, 2026 |
| FY2025 | Oct 15, 2024 | 32.02M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 1.43M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 13.37M | Apr 1, 2024 |